引用本文:王丽洁,徐文娟,陈文,等.国家基本药物目录与WHO示范目录的差异分析[J].中国卫生政策研究,2012,5(7):21-25 |
|
国家基本药物目录与WHO示范目录的差异分析 |
投稿时间:2012-05-24 修订日期:2012-06-24 PDF全文浏览 HTML全文浏览 |
王丽洁1, 徐文娟1, 陈文1, 张璐莹1, 蒋虹丽1 |
复旦大学公共卫生学院 |
摘要:目的:通过比较我国国家基本药物目录与WHO 2011版示范目录的差异,为我国修订和完善国家基本药物目录提供参考。方法:采用WHO官网公开的WHO 1977—2011年基本药物示范目录汇总表录入国家基本药物目录西药,进行矩阵表分析。结果:我国国家基本药物目录构成、药物分类方式和适用对象等基本要素,遴选标准、方法等遴选机制,以及收录药品的品种和类别与WHO 2011版示范目录存在差异。两目录对同一治疗组推荐药品有所区别,部分国家基本药物品种已被WHO示范目录删除。结论与建议:通过与WHO示范目录比较,可以发现我国基本药物目录存在一些不足,需要进一步完善目录要素和构成,完善遴选机制,并根据WHO示范目录药品的系统证据对现有基本药物品种进行调整。 |
关键词:基本药物 国家基本药物目录 WHO示范目录 比较研究 |
基金项目:卫生部统计信息中心资助课题 |
|
Comparative analysis between the national essential medicines list and the WHO 2011 model list |
|
|
Abstract:Objective: The paper aims to comparatively analyze the national essential medicines list (NEML) with the WHO 2011 Model list for NEML revision. Method: Matching NEML medicines into the spreadsheet of historical master list (1977—2011) available on WHO website. Result: the discrepancies between the two lists include elements such as list components, medicines classification and application, selection mechanism with criteria and methods, and the specific kind. Two lists selected different medicines for the same therapeutic group and some of China essential medicines have been deleted by WHO list. Conclusion and suggestion: Through the comparison, the deficit of NEML has been revealed, which could be improved by revision of list elements and components, improvement on selection mechanism, and adjustment of medicines based on the systematic review of evidences WHO provided. |
Key words:Essential medicines National essential medicines list WHO model list Comparative analysis |
摘要点击次数: 2899 全文下载次数: 5071 |
|
|